Norges Bank Buys Shares of 495,456 Axsome Therapeutics, Inc. $AXSM

Posted by Brenda Bartman on Jun 6th, 2026

Norges Bank acquired a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 495,456 shares of the company’s stock, valued at approximately $90,490,000.

Several other institutional investors also recently modified their holdings of AXSM. Optiver Holding B.V. grew its holdings in shares of Axsome Therapeutics by 82.3% during the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after purchasing an additional 130 shares in the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Axsome Therapeutics during the 3rd quarter worth approximately $38,000. Advisory Services Network LLC acquired a new stake in shares of Axsome Therapeutics during the 3rd quarter worth approximately $40,000. UMB Bank n.a. grew its holdings in shares of Axsome Therapeutics by 214.4% during the 3rd quarter. UMB Bank n.a. now owns 371 shares of the company’s stock worth $45,000 after purchasing an additional 253 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Axsome Therapeutics by 65.4% during the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company’s stock worth $49,000 after purchasing an additional 106 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Transactions at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 233 shares of the company’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the completion of the sale, the chief operating officer owned 4,517 shares in the company, valued at approximately $1,030,689.06. This represents a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Mark Coleman sold 5,537 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $223.39, for a total value of $1,236,910.43. Following the completion of the sale, the director owned 29,603 shares of the company’s stock, valued at $6,613,014.17. This represents a 15.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 29,787 shares of company stock worth $6,470,391 over the last 90 days. 20.60% of the stock is owned by insiders.

Axsome Therapeutics Trading Up 0.4%

Shares of AXSM opened at $232.32 on Friday. The company has a market cap of $11.96 billion, a price-to-earnings ratio of -62.28 and a beta of 0.61. Axsome Therapeutics, Inc. has a 52-week low of $96.09 and a 52-week high of $242.41. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.32 and a current ratio of 1.39. The stock has a fifty day moving average price of $202.66 and a two-hundred day moving average price of $178.42.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The firm had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The business’s quarterly revenue was up 57.4% compared to the same quarter last year. Analysts predict that Axsome Therapeutics, Inc. will post -2.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AXSM. Wells Fargo & Company lifted their price objective on Axsome Therapeutics from $225.00 to $255.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Guggenheim boosted their price target on Axsome Therapeutics from $245.00 to $260.00 and gave the company a “buy” rating in a research note on Monday, May 4th. Wolfe Research started coverage on Axsome Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $230.00 price target on the stock. Jefferies Financial Group lifted their price objective on Axsome Therapeutics from $245.00 to $275.00 and gave the company a “buy” rating in a research report on Monday, May 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $251.26.

Check Out Our Latest Stock Report on Axsome Therapeutics

Axsome Therapeutics Company Profile

(Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.